UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer

Current treatment options in oncology, 2015-12, Vol.16 (12), Article 57

2015

Volltextzugriff (PDF)

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease

The New England journal of medicine, 2021-11, Vol.385 (22), p.2036-2046

2021

Volltextzugriff (PDF)

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

The New England journal of medicine, 2022-03, Vol.386 (12), p.1132-1142

2022

Volltextzugriff (PDF)

Update on combined immunotherapy for the treatment of advanced renal cell carcinoma

Human vaccines & immunotherapeutics, 2023-12, Vol.19 (1), p.2193528-2193528

2023

Volltextzugriff (PDF)

Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0

Cancers, 2023-07, Vol.15 (14), p.3717

2023

Volltextzugriff (PDF)

Androgen pathway resistance in prostate cancer and therapeutic implications

Expert opinion on pharmacotherapy, 2015-07, Vol.16 (10), p.1521-1537

2015

Volltextzugriff (PDF)

CDK12 -Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors

JCO precision oncology, 2020-11 (4), p.370-381

2020

Volltextzugriff (PDF)

Radium‐223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration‐Refractory Prostate Cancer: Final Safety and Efficacy Results

The oncologist (Dayton, Ohio), 2021-12, Vol.26 (12), p.1006-e2129

2021

Volltextzugriff (PDF)

Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma

Current treatment options in oncology, 2018-01, Vol.19 (1), p.6-12, Article 6

2018

Volltextzugriff (PDF)

Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial

BMC cancer, 2024-04, Vol.24 (1), p.493-11, Article 493

2024

Volltextzugriff (PDF)

Neuroendocrine differentiation in usual‐type prostatic adenocarcinoma: Molecular characterization and clinical significance

The Prostate, 2020-09, Vol.80 (12), p.1012-1023

2020

Volltextzugriff (PDF)

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease

The New England journal of medicine, 2021-11, Vol.385 (22), p.2036-2046

2021

Volltextzugriff (PDF)

Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022

Current oncology reports, 2022-09, Vol.24 (9), p.1201-1208

Maughan, Benjamin L.

2022

Volltextzugriff (PDF)

Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma

PloS one, 2019-01, Vol.14 (1), p.e0210415-e0210415

2019

Volltextzugriff (PDF)

Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis–Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting

European urology focus, 2023-01, Vol.9 (1), p.106-109

2023

Volltextzugriff (PDF)

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide

Journal of clinical oncology, 2017-07, Vol.35 (19), p.2149-2156

2017

Volltextzugriff (PDF)

Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration‐Resistant Prostate Cancer: A Retrospective Study

The Prostate, 2017-01, Vol.77 (1), p.33-40

2017

Volltextzugriff (PDF)

Papillary Renal Cell Carcinoma: A Review of Prospective Clinical Trials

Current treatment options in oncology, 2023-09, Vol.24 (9), p.1199-1212

2023

Volltextzugriff (PDF)

Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

Journal of clinical oncology, 2021-11, Vol.39 (33), p.3725-3736

2021

Volltextzugriff (PDF)

Combination therapy with radium-223 and enzalutamide in castration-resistant prostate cancer

Clinical advances in hematology & oncology, 2021-12, Vol.19 (12), p.764

Maughan, Benjamin L

2021

Volltextzugriff (PDF)

Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA

Frontiers in oncology, 2022-09, Vol.12, p.966534-966534

2022

Volltextzugriff (PDF)

Clinical, Genomic, and Transcriptomic Characteristics of Patients with Metastatic Renal Cell Carcinoma Who Developed Thromboembolic Events

Journal of kidney cancer and VHL, 2024-01, Vol.11 (3), p.13-22

2024

Volltextzugriff (PDF)

A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers

Heliyon, 2022-09, Vol.8 (9), p.e10583-e10583, Article e10583

2022

Volltextzugriff (PDF)

Detection of BRCA1 , and BRCA2 Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting

Biomedicines, 2022-12, Vol.10 (12), p.3170

2022

Volltextzugriff (PDF)

Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers

Frontiers in oncology, 2017-04, Vol.7, p.56-56

2017

Volltextzugriff (PDF)

1 – 25 von 198

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(178)
Mit Volltextzugriff
(147)

Publikationsform

Artikel
(195)
Buchkapitel
(1)
Berichte
(1)
Texte
(1)

Sprache

Englisch
(198)

Erscheinungsjahr

n.n

Thema

Science & Technology
(85)
Life Sciences & Biomedicine
(82)
Oncology
(62)
Humans
(53)
Male
(44)
Prostate Cancer
(29)
Urology & Nephrology
(28)
Metastasis
(25)
Aged
(23)
Middle Aged
(21)
Metastases
(17)
Patients
(17)
Prostatic Neoplasms, Castration-Resistant - Drug Therapy
(17)
Retrospective Studies
(17)
Immunotherapy
(14)
Kidney Cancer
(14)
Renal Cell Carcinoma
(14)
Castration
(13)
Prostatic Neoplasms, Castration-Resistant - Pathology
(12)
Aged, 80 And Over
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

Update on combined immunotherapy for the treatment of advanced renal cell carcinoma

Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0

Androgen pathway resistance in prostate cancer and therapeutic implications

CDK12 -Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors

Radium‐223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration‐Refractory Prostate Cancer: Final Safety and Efficacy Results

Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma

Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial

Neuroendocrine differentiation in usual‐type prostatic adenocarcinoma: Molecular characterization and clinical significance

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease

Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022

Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma

Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis–Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide

Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration‐Resistant Prostate Cancer: A Retrospective Study

Papillary Renal Cell Carcinoma: A Review of Prospective Clinical Trials

Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

Combination therapy with radium-223 and enzalutamide in castration-resistant prostate cancer

Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA

Clinical, Genomic, and Transcriptomic Characteristics of Patients with Metastatic Renal Cell Carcinoma Who Developed Thromboembolic Events

A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers

Detection of BRCA1 , and BRCA2 Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting

Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers

Suchergebnisse filtern